AU709196B2 - Use of alendronate for the prevention of osteoporosis - Google Patents
Use of alendronate for the prevention of osteoporosis Download PDFInfo
- Publication number
- AU709196B2 AU709196B2 AU58824/96A AU5882496A AU709196B2 AU 709196 B2 AU709196 B2 AU 709196B2 AU 58824/96 A AU58824/96 A AU 58824/96A AU 5882496 A AU5882496 A AU 5882496A AU 709196 B2 AU709196 B2 AU 709196B2
- Authority
- AU
- Australia
- Prior art keywords
- alendronate
- salt
- osteoporosis
- woman
- postmenopausal woman
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45819595A | 1995-06-02 | 1995-06-02 | |
| US08/458195 | 1995-06-02 | ||
| PCT/US1996/007912 WO1996038156A1 (en) | 1995-06-02 | 1996-05-29 | Use of alendronate for the prevention of osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU5882496A AU5882496A (en) | 1996-12-18 |
| AU709196B2 true AU709196B2 (en) | 1999-08-26 |
Family
ID=23819759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU58824/96A Ceased AU709196B2 (en) | 1995-06-02 | 1996-05-29 | Use of alendronate for the prevention of osteoporosis |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0828496A1 (bg) |
| JP (1) | JPH10506648A (bg) |
| KR (1) | KR19990022436A (bg) |
| CN (1) | CN1192685A (bg) |
| AU (1) | AU709196B2 (bg) |
| BG (1) | BG63103B1 (bg) |
| BR (1) | BR9609020A (bg) |
| CA (1) | CA2222318A1 (bg) |
| CZ (1) | CZ381197A3 (bg) |
| EA (1) | EA000677B1 (bg) |
| EE (1) | EE03306B1 (bg) |
| HU (1) | HUP9900659A3 (bg) |
| IL (1) | IL118422A0 (bg) |
| IS (1) | IS4617A (bg) |
| NO (1) | NO975527D0 (bg) |
| NZ (1) | NZ308935A (bg) |
| PL (1) | PL323669A1 (bg) |
| SK (1) | SK159597A3 (bg) |
| TR (1) | TR199701482T1 (bg) |
| WO (1) | WO1996038156A1 (bg) |
| ZA (1) | ZA964465B (bg) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| SE9901272D0 (sv) * | 1999-04-09 | 1999-04-09 | Astra Ab | New improved formulation |
| KR100317935B1 (ko) * | 1999-10-20 | 2001-12-22 | 유승필 | 대사성 골질환 치료용 약제조성물 및 이의 제조방법 |
| JP2004528365A (ja) * | 2001-05-02 | 2004-09-16 | ノバルティス アクチエンゲゼルシャフト | 骨再吸収症および骨粗しょう症の処置または予防におけるビスホスホネートの吸入投与方法 |
| JP2010043119A (ja) * | 2009-10-16 | 2010-02-25 | Gador Sa | 骨の代謝病の予防および／または治療のための組成物、その組成物の調製方法およびその使用 |
| KR102472749B1 (ko) * | 2022-01-18 | 2022-12-02 | 주식회사 위엔씨 | 유해가스제거 및 항균탈취기능을 함유한 흡착소재 제조방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5366965A (en) * | 1993-01-29 | 1994-11-22 | Boehringer Mannheim Gmbh | Regimen for treatment or prophylaxis of osteoporosis |
| US5462932A (en) * | 1994-05-17 | 1995-10-31 | Merck & Co., Inc. | Oral liquid alendronate formulations |
-
1996
- 1996-05-27 IL IL11842296A patent/IL118422A0/xx unknown
- 1996-05-29 CA CA002222318A patent/CA2222318A1/en not_active Abandoned
- 1996-05-29 SK SK1595-97A patent/SK159597A3/sk unknown
- 1996-05-29 KR KR1019970708917A patent/KR19990022436A/ko not_active Application Discontinuation
- 1996-05-29 TR TR97/01482T patent/TR199701482T1/xx unknown
- 1996-05-29 CN CN96196075A patent/CN1192685A/zh active Pending
- 1996-05-29 HU HU9900659A patent/HUP9900659A3/hu unknown
- 1996-05-29 AU AU58824/96A patent/AU709196B2/en not_active Ceased
- 1996-05-29 JP JP8536616A patent/JPH10506648A/ja active Pending
- 1996-05-29 CZ CZ973811A patent/CZ381197A3/cs unknown
- 1996-05-29 BR BR9609020A patent/BR9609020A/pt not_active Application Discontinuation
- 1996-05-29 EE EE9700308A patent/EE03306B1/xx not_active IP Right Cessation
- 1996-05-29 WO PCT/US1996/007912 patent/WO1996038156A1/en not_active Application Discontinuation
- 1996-05-29 EP EP96920553A patent/EP0828496A1/en not_active Withdrawn
- 1996-05-29 PL PL96323669A patent/PL323669A1/xx unknown
- 1996-05-29 EA EA199700449A patent/EA000677B1/ru not_active IP Right Cessation
- 1996-05-29 NZ NZ308935A patent/NZ308935A/en unknown
- 1996-05-31 ZA ZA964465A patent/ZA964465B/xx unknown
-
1997
- 1997-11-19 IS IS4617A patent/IS4617A/is unknown
- 1997-11-20 BG BG102060A patent/BG63103B1/bg unknown
- 1997-12-01 NO NO975527A patent/NO975527D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO975527L (no) | 1997-12-01 |
| EP0828496A1 (en) | 1998-03-18 |
| EE03306B1 (et) | 2000-12-15 |
| EA000677B1 (ru) | 2000-02-28 |
| HUP9900659A3 (en) | 2002-12-28 |
| IL118422A0 (en) | 1996-09-12 |
| BR9609020A (pt) | 1999-07-06 |
| HUP9900659A2 (hu) | 2001-04-28 |
| CN1192685A (zh) | 1998-09-09 |
| ZA964465B (en) | 1996-12-11 |
| WO1996038156A1 (en) | 1996-12-05 |
| KR19990022436A (ko) | 1999-03-25 |
| SK159597A3 (en) | 1998-06-03 |
| NO975527D0 (no) | 1997-12-01 |
| CZ381197A3 (cs) | 1998-06-17 |
| IS4617A (is) | 1997-11-19 |
| JPH10506648A (ja) | 1998-06-30 |
| NZ308935A (en) | 2000-07-28 |
| AU5882496A (en) | 1996-12-18 |
| TR199701482T1 (xx) | 1998-03-21 |
| EA199700449A1 (ru) | 1998-06-25 |
| BG63103B1 (bg) | 2001-04-30 |
| PL323669A1 (en) | 1998-04-14 |
| BG102060A (bg) | 1998-07-31 |
| CA2222318A1 (en) | 1996-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI118296B (fi) | Oraalisia nestemäisiä alendronaattikokoonpanoja | |
| AU2006213981A1 (en) | Folic acid-containing pharmaceutical compositions, and related methods and delivery systems | |
| ZA200206551B (en) | Drospirenone for hormone replacement therapy | |
| EA000964B1 (ru) | Способ лечения или предупреждения остеопороза | |
| AU690431B2 (en) | Method of lessening the risk of non-vertebral bone fractures | |
| KR20010015918A (ko) | 안면홍조를 감소시키기 위한 플루옥세틴 히드로클로라이드 | |
| AU709196B2 (en) | Use of alendronate for the prevention of osteoporosis | |
| US20020169148A1 (en) | Use of alendronate for the prevention of osteoporosis | |
| AU703887B2 (en) | Bisphosphonate therapy for bone loss associated with rheumatoid arthritis | |
| AU713824B2 (en) | Prevention of tooth loss by the administration of alendronate or its salts | |
| KR19980702209A (ko) | 척추 골절의 위험을 경감시키는 방법 | |
| AU692155B2 (en) | Method and composition for treatment of osteoporosis | |
| Standard | Pr TEVA-RISEDRONATE | |
| MXPA97009426A (en) | Use of alendronate to prepare compositions for the prevention of osteoporo | |
| JPH0132804B2 (bg) | ||
| JPH04266822A (ja) | システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤 | |
| CN115335038A (zh) | 用于治疗痛经和/或经前期综合征(pms)的药物组合物 | |
| CN1187130A (zh) | 用二磷酸盐预防与免疫抑制疗法有关的骨损失 | |
| MXPA97009906A (en) | Use of bisphosphonates to prepare compositions to prevent loss of associated bone conterapia immunosupres | |
| MXPA97006277A (en) | The use of alendronate to prepare compositions to reduce the risk of non-vertebrate bit fractures | |
| MXPA98001222A (en) | Quecontain composition mefenamic acid in association with code |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |